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ABSTJuCT 
MicroRNAs are expressed abundantlr in the placenta throughout pregnancy. We 
have previously reported that miR-378a-5pl promotes trophoblast cell proliferation and 
i 
invasion. To further understand the role ofm~R-378a-5p during placental development, we 
I 
determined if it may also regulate the diff~rentiation of cytotrophoblast (CTB) into the 
I 
syncytiotrophoblast (STB). Using BeWo c911s, we found that miR-378a-5p was down-
regulated during Forskolin-induced STB differentiation. Transfection of miR-378a-5p 
mimic into Be Wo cells decreased the formation of multinucleated STB, mRNA levels of 
differentiation markers and E-cadherin levels. However, inhibition of endogenous miR-
1 
378a-5p by anti-miR-378a-5p increased cell !fusion, induced STB marker gene expression 
and decreased E-cadherin levels. Lucifera~e reporter assay and real-time PCR analysis 
showed that CCNG2 is a target of miR-378a-5p. Taken together, these findings 
I 
demonstrate that miR-378a-5p is a negative regulator of STB differentiation. This study 
also provides initial evidence that CCNGf p~omotes trophoblast differentiation and may be 
involved in miR-378a-5p-regulated STB fo~ation. 
ii 
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Chapter I. Introduction 
I. MicroRNAs 
MicroRNAs (miRNAs) are small (20-22 nucleotides), single stranded, non-coding 
regulatory RNAs that post-transcriptionally :modulate the expression of their target genes 
(1). Generally, miRNAs negatively regulate gene expression by partial complementary 
binding to the 3' untranslated region (UTR) pf target mRNAs, resulting in mRNA cleavage 
or translational repression (2). The mech~sm of silencing or repressing mRNA is 
. I 
dependent on the degree of complementarity between the miRNA and the target sequence. 
I 
Studies have demonstrated that miRNAs play important roles in cell proliferation (3-4), 
differentiation (5-6), apoptosis (4-6) and m~y physiological processes (7-9). 
I 
1.1. Discovery of microRNAs 
Two decades ago (1993), Victor Ambros and his colleagues discovered the first 
I 
miRNA, lin-4, in Caenorhabditis elegans ;(C.elegans) that controls the timings of post-
I 
embryonic development. Interestingly, th~y found that lin-4 (22 nucleotide non-coding 
RNA) does not encode a protein product but represses the protein expression by binding to 
the 3'UTR of the lin-14 gene (10). Seven years later, the second miRNA, let-7 (21 
I 
i 
nucleotide non-coding RNA) was discov~red in C. elegans. Subsequently, the let-7 
I 
homologs were detected in human, zebrafish, Drosophila, annelids and mollus·cs (11 ). A 
I 
total of over one hundred additional mi~As were identified in Drosophila, human and 
worms in less than one year after the disc?very of let-7. Furthermore, most of the cloned 
1 
miRNAs are highly conserved in closely rel~ted species such as human and mouse (12-13) 
I 
or C. elegans and C. briggsae (14) while others are broadly conserved among the animal 
! 
I 
lineages (15-16). For instance, more than! one third of the C. elegans miRNAs are 
I 
homologous with human miRNAs (13). To: date, more than a thousand of miRNAs have 
I 
been identified in humans and this number is still increasing. It has been reported that one 
i 
miRNA targets many mRNAs (17) and many miRNAs can target one mRNA (17-18). 
I 
1.2. Biogenesis of miRNA 
MicroRNA genes are transcribed ilito primary transcripts (pri-miRNAs) in the 
i 
nucleus by RNA polymerase II (pol II). The~e primary miRNAs are either derived from the 
I 
introns of protein coding genes, exons of n~ncoding genes, or from intergenomic regions 
I 
within the genome (35). Next, pri-miRNlAi.s which are greater than 1000 bases are 
I 
I 
I 
polyadenylated and capped with 7-methylg*anosine are folded into hairpin structures (1, 
I 
19). Pri-miRNAs are processed and cleai"ed into stem-loop precursor miRNAs (pre-
1 
miRNAs, 60-100 nucleotides) by the nuclear RNase III enzyme Drosha and its coactivator 
I 
I 
I 
DGCR8 (20). The pre-miRNAs are transported from the nucleus into the cytoplasm 
through the inte~action with Ran-GTP and r~ceptor Exportin-5. The pre-miRNA is further 
cleaved by a cytoplasmic RNase III enzym~ Dicer. Dicer is a member of the RNase III 
I 
superfamily of bidentate nucleases and its f~ction is to remove the base pairs and the loop 
I 
structure of pre-miRNA and form h 22 nucleotide double stranded duplex 
I 
I 
miRNA:miRNA * (21 ). Finally, the RNA dhplex unwinds and the single stranded mature 
miRNA is incorporated into the RNA-in~uced silencing complex (RISC). Argonaute 
2 
proteins are the core component of the RISC;complex, acting as target recognition modules 
I 
of the RISC (22-25). The incorporation of miRNA into the RISC regulates the expression 
of target genes by binding to complementaty sequences in the 3 'UTR of target mRNAs 
I 
I 
following the Watson and Crick principle of
1
base pairing (23). Therefore, gene silencing is 
based on the degree of miRNA-mRNA cofriplementarity which takes place in the seed 
I 
region of miRNA and target mRNA. Mic)."oRNA which has a perfect or near perfect 
complementarity with the target mRNA results in mRNA degradation while imperfect or 
I 
i 
partial complementarity between miRNA and target mRNA results in inhibition of protein 
synthesis (26). However, it has been reporte4 that some miRNAs can bind to the target sites 
I 
in the 5'UTR as efficiently as 3'UTR and still successfully repress the target mRNAs (27) 
[Fig. 1]. 
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Fig 1. Overview of microRNA biogenesis and regulation. MicroRNA genes are 
transcribed into primary transcripts (pri-miiRNAs) by RNA polymerase II (Pol II). Pri-
miRNAs are cleaved by Drosha into precursor miRNAs (pre-miRNAs) that have a stem-
loop structure. Pre-miRNAs are exported tol the cytoplasm where they are further cleaved 
by Dicer and form miRNA duplexes. Th~ duplex is unwinded and mature miRNA is 
incorporated into the RISC complex, binds! to the 3 'UTR of target mRNAs and induces 
gene silencing either by causing mRNA deg~adation or translation inhibition. 
I 
4 
1.3. Classification of miRNAs 
Discovery of miRNA opened a new chapter in the field of molecular biology. 
I 
Victor Ambros presented universal guideline~ for the identification and annotation of newly 
I 
I 
discovered microRNAs. Moreover, he srtggested that miRNA must follow specific 
I 
I 
expression and biogenesis criteria (89). Theinaming criteria of miRNA follows the rule of 
three -latter prefix, capitalization, hyphenatibn and italics. The pre-miRNA is annotated by 
"mir". Mature miRNAs used a "miR" prefi~ and followed a unique identification number 
I 
(e.g., miR-378) which are assigned sequ'entially and not depends on the organism. 
I 
I 
Therefore, the identical miRNAs have the same number. Letter preceding the "miR" prefix 
I 
I 
represents the organism in which miRNA ~s found. For example, hsa-miR-378 refers to 
I 
I 
Homo sapiens. A letter following the identification number represents its relation to another 
I 
I 
i 
miRNA. These two miRNA are slightly different in sequence from each other by 1 or 2 
I 
nucleotide (i.e. miR378a is related to miR37~b) (89). 
Based on thermal stability it was th<?ught that one strand of miRNA is biologically 
I 
active and referred as miR, and the other was considered as an inactive strand and that 
i 
strand was called miR* (miRNA star or pa~senger strand). It was believed that miR* will 
be degraded and act as a minor product in Some cell lineages. However, more recent work 
I 
have shown that in many cases, both strcimds of miRNA are functional and therefore, 
mature miRNAs from the same pre-miRNA1are named as miR-5p and miR-3p (90). 
5 
·1 
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1.4. MicroRNA target prediction and validation 
I 
Identification of miRNA target genes is very challenging because of the partial 
I 
complementarity sequence between the ta.fget mRNAs and miRNAs. Therefore, both 
i 
computational and experimental approache~ are needed to identify miRNA target genes 
I 
(77). Bioinformatic prediction analysis otl target genes is mainly based on sequence 
matching between miRNA and mRNA, duplex thermal stability, secondary structure of the 
I 
I 
I 
miRNA/mRNA duplex, three-dimensional cpmplex analysis and conservation of the target 
site (78). Several computational predictiqn programs, such as miRanda, TargetScan, 
TargetScanS, RNAhybrid, DIANA-microT, 1 PicTar, RNA22 and FindTar, are available to 
identify potential target genes. 
The validation of a predicted target ~ene of a miRNA can be done by experimental 
I 
approaches, including reporter assays, west~m blot analysis, and real-time PCR. The most 
I 
I 
direct method to confirm a miRNA target gene is the Luciferase reporter gene assay. In 
• I 
I 
this assay the luciferase coding sequence is fused with the 3 'UTR of a potential target gene. 
If the 3'UTR has a specific target site of J particular miRNA, expression of the miRNA 
I 
would result in a decrease in the luciferase activity (79). In addition to luciferase assay, 
I 
quantitative real-time PCR and Western blot methods are commonly used to detect the 
mRNA and protein levels respectively in n#RNA transfected or knock-down cells. These 
I 
approaches are accurate to quantify the ch<;mges in mRNA and protein level of a miRNA 
target genes (78-79). 
6 
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1.5. miR-378a-5p 
The niiR-378a-5p was originally cloned from promyelocytic leukemia and named 
miR-422b (80). Landgraf et al. later showed that the miR-422b and miR-422a loci are 
I 
unrelated and thus miR-422b was renamed 4s miR-378 (81). This miRNA was later called 
miR-378* but more recently, several miRN}\.s related to miR-378 were characterized and 
thus miR-378* was renamed to miR-378a-5j). 
I 
It has been reported that miR-378a-pp plays important roles in regulating cellular 
I 
processes. Recently, our lab has demoJstrated that miR-378a-5p is predominantly 
I 
expressed in first and second trimester hur;nan placenta and it promotes trophoblast cell 
I 
I 
survival, migration and invasion by targetin!? Nodal (82). In porcine ovary, miR-378a-5p is 
expressed in granulosa cells and decreases ~he aromatase expression. Aromatase (estrogen 
i 
synthetase) is a key enzyme in the biosyntqesis of estradiol and play an important role in 
ovarian follicular development and is requfred for female reproduction (83). It is also a 
I 
I 
significant regulator in skeletal muscle differentiation (84). In addition, miR-378a-5p 
I 
I 
regulates nephronectin (extracellular matrix protein) mediated differentiation in the 
I 
osteoblastic cell line (85) and promotes cell survival, tumor growth, and angiogenesis by 
targeting SuFu and Fus-1 expression (86). Ffthermore, miR-378a-5p has been identified as 
I 
a novel target of the c-Myc oncoprotein and: promotes cellular transformation (87). Finally, 
i 
it is strongly expressed in the mapunali~n heart and controls cardiac hypertrophy by 
I 
suppressing the MAP kinase signaling path~ays (88). 
I 
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II. Human Placenta 
Placenta plays critical roles throughout the entire pregnancy and supports the 
I 
I 
growth and development of the fetus. Servjng as the interface between the maternal and 
I 
I 
fetal environment, the placenta is involved ~n the exchange of respiratory gases, nutrients 
and waste products between the mother arld the growing fetus (36). Moreover, it is an 
I 
endocrine organ which produces a number of pregnancy- associated hormones and growth 
factors that regulate maternal physiology apd fetal development. Furthermore, placenta 
I 
helps to prevent the rejection of fetal allogr~ft (37). Therefore, placenta plays a vital role in 
the survival and health of the embryo. 
11.1. Implantation 
Development of placenta is an extremely regulated and continuous process that 
I 
I 
begins at the time of fertilization. During embryonic development, the fertilized egg 
I 
undergoes a series of mitotic divisions and forms a ball of cells called "Morula". 
Compaction of morula is the first event of ;morphogenic and cellular differentiation. Cells 
in morula align themselves in the outer pe1ripheral region and create a fluid filled cavity 
called "Blastocyst". This blastocyst con,sists of two primary cell types, the outer 
trophoectoderm cells called trophoblast, 1 which later form the placenta and fetal 
membranes, and the inner cell mass forms tlle embryo (38). 
8 
Once the blastocyte reaches the uterine cavity it orients its pole (inner cell mass) 
I 
I 
towards the uterine epithelium and attaches tb the uterine wall. The process of implantation 
i 
is accomplished by the highly adhesive and ipvasive trophectodermal cells of the blastocyst 
(trophoblast) which appose, attach and fitjally invade the uterine epithelium. Invasion 
I 
I 
results in the digestion of the epithelial membrane and as a result, the blastocyst reaches the 
I 
endometrial stroma (38, 39) [Fig. 2]. 
,9 
Fertilized egg 
Blastocyst 
Adhesion and Invasion 
Uterine cavity Syncytiotrophoblast 
-
Fig 2. Blastocyst implantation steps. A series of mitotic divisions convert the fertilized 
egg to morula. The cells in morula aligrl themselves and form blastocyst. Once the 
blastocyte reaches the uterine cavity, it starts hatching. Later on, adhesion and invasion 
result in digestion of uter~ne epithlium and it finally implants itself in the uterus. 
Mononuclear cytotrophoblasts fuse to i form a multinucleated syncytium or 
syncytiotrophoblast. The image was drawn b~sed on (Bischof P 2005). 
I 
I 
10 
11.2. Trophoblast Differentiation 
Trophoblasts, the precursor cells df placenta, play a vital role in the embryo 
implantation and placental development. Trophoblast progenitor cells differentiate into two 
distinct pathways (extravillous and villous). :in the extravillous (EVT) or invasive pathway, 
I 
cytotrophoblasts (CTB, inner layer of trophoblast) proliferate and differentiate into an 
I 
invasive phenotype and penetrate into the m~temal decidua and myometrium. In the villous 
or syncytial pathway, fusion of mononpclear CTB results in the formation of a 
I 
multinucleated structure called syncytium or syncytiotrophoblast (STB) and this process is 
referred as syncytialization (40-41) [Fig 3] .. 
The multinucleated STB is formeq by the fusion of underlying mononucleated 
CTBs and it covers the floating villi surrounded by the maternal blood. As the STB is non-
proliferative and lacks the ability of nuclear division, donation of CTBs is essential for 
syncytial health and function (37). The STB is responsible for nutrient and gas exchange 
( 42). Moreover, it is the site of synthesis of various growth factors and hormones, such as 
human chorionic gonadotropin (hCG) and ~uman placental lactogen (hPL) ( 42-43). STB is 
I 
i 
the main source of progesterone during ~regnancy and its level of synthesis gradually 
I 
increases over the entire pregnancy period ( 44 ). 
11 
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STB 
Fig 3. Trophoblast differentiation pathways. Trophoblast differentiates into two distinct 
pathways during placental development. In the extravillous or invasive pathway cells 
proliferate, migrate and finally invade intb the uterus. In the villous or fusion pathway 
mononuclear cytotrophoblast (CTB) fuse! to form a multinucleated syncytium called 
I 
syncytiotrophoblast (STB). Formation of S[B is associated with changes in expression of 
I 
marker genes. , 
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'I 
I 
I 
Therefore, syncytiotrophoblast form~tion plays vital roles in human placentation 
I 
and any disturbance in the trophoblast: differentiation could result in pregnancy 
i 
complications. For example, defective or r~tarded syncytium formation produces severe 
pathological conditions such as Down's syµdrome or Trisomy of chromosome 21 which 
occurs because of the hyperactivity of a c){toplasmic enzyme (coded by a gene which is 
I 
located on chromosome 21) and impairs the trophoblast differentiation towards fusion ( 46). 
I 
Differentiation of CTB into STB can be studied by morphological (aggregation and 
I 
fusion of cells) and biochemical changes (expression of genes) (17) .. Morphological 
I 
I 
differentiation can be studied by microscopic observation of cell fusions through 
I 
immunofluorescent staining using antibodies against cell surface molecules, such as E-
1 
I 
cadherin (17, 65). Loss of E-cadherin is a iharker for STB differentiation as E-cadherin is 
I 
reduced when CTBs are fused to form S~B (65-66). During STB differentiation, cells 
\ 
begin to express genes that synthesize and $ecrete a vast array of endocrine products such 
as hCG and hPL (57). In addition to thesei hormones, a number of genes are commonly 
used as markers of STB differentiation, such as syncytin-1 and 2, galactoside-binding 
I 
I 
soluble lectin 13 (LGALS 13) and placental alkaline phosphatase (ALPP). 
I 
11.2.1. Human Chorionic Gonadotropin (h~G) and Placental Lactogen (hPL) 
Human Chorionic gonadotropin (hQG) belongs to the glycoprotein family and is 
I 
composed of a and B subunits. The hCG ha~ paracrine effects on several processes such as 
implantation and angiogenesis (58). Moreov~r, it rescues the corpus luteum from involution 
by maintaining progesterone secretion (59).~ Since hCG is produced from the STB, it is 
I 
I 
used as a IQarker of syncytialization~ Hunian placental lactogen (hPL) is a polypeptide 
I 
hormone and is secreted from the STB throughout the pregnancy. It alters the maternal 
I 
carbohydrate and lipid metabolism for fetal nutrient requirement (59,125). 
11.2.2. Syncytin-1 and Syncytin-2 
Human endogenous retroviruses (lfIERVs) constitute about 8% of the human 
I 
genome and several of HERVs are expressed in the placenta (60). Studies have 
I 
demonstrated that the trophoblast expresses lthe two fusogenic retroviral envelope proteins, 
I 
Syncytin-1 (encoded by HERV-W) and Syncytin 2 (encoded by HERV-FRD) (61). It has 
I 
I 
been reported that Syncytin-1 plays an essential role in the formation of STB and a 
decrease in the expression of Syncytin-1 qas been associated with pregnancy-associated 
I 
anomalies, such as preeclampsia (60). Syµcytin-2 is also placental specific and plays a 
vital role in trophoblast cell fusion (62). 
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11.2.3. LGALS13 
The placental-specific Lectin, Galadoside Binding, Soluble 13, LGALS13, (also 
I 
known as PP13) belongs to the galectin fam~ly and is predominantly localized to the STB 
apical membrane (63). It has been suggest~d that LGALS13 can be used as a potential 
serum marker for the diagnosis of pregnanpy complications as its levels are reduced in 
patients with pre-eclampsia ( 68). 
11.2.4. Placental Alkaline Phosphatase 
' ' 
Placental Alkaline Phosphatas~ (ALPP or PALP) is an enzyme produced by STB 
i 
! 
during pregnancy, and therefore used as a: marker of STB differentiation (64). It is a 
membrane · bound glycosylated enzyme ~esponsible for dephosphorylation of many 
I 
proteins. ALPP is synthesized by placenta throughout the entire gestation period. ALPP is 
I 
localized at the apical and basal plasma meµtbrane in term villous trophoblast (67) and is 
I 
! 
used as an apical marker enzyme for the isolation and purification of placental brush border 
I 
membranes (67). 
I 
11.3.Regulation of syncytiotrophobl~st differentiation 
I 
I 
Primary cultures of CTB cells or cell lines, such as Be Wo, can be induced to 
differentiate into STB by pharmacological 
1
agents that elevate intracellular cAMP levels 
15 
( 48-49). Many factors, including transcripti<?n factors, hormones and growth factors, and 
I 
miRNAs have been shown to regulate STB d~fferentiation (40). 
11.3.1. Transcription factors 
Syncytial fusion is stimulated by tran~criptional factors such as Glial cells missing -
I 
1 (GCM-1). GCM-1 is localized within the nuclei of a subset of CTBs cells (51) and 
involved in the transcription of syncytin and placenta specific genes. Transcription factors 
I 
I 
of the activating protein-2 (AP-2) family ; members are regulated by cAMP and play 
I 
important roles in the syncytial fusion. The AP-2 transcription factors family members are 
I 
I 
required for the expression of the syncytium specific genes such as CGB, hPL or CYP 19 
I 
(91). Moreover, PPARy regulates the STB ldifferentiation in a ligand-dependent manner. 
I 
PPARy interacts with the promoter region of1the CGP-5 gene and affects cop transcription, 
I 
thus controls the syncytium formation (92-93). 
11.3.2. Hormones and growth factors 
Trophoblast differentiation into the STB pathway is stimulated by hCG, 
glucocorticoids and estradiol. Human chorionic gonadotropins act as an autocrine, 
paracrine, intracrine and endocrine regulator: and promote syncytial fusion, thus able to self-
, 
regulate the mRNA levels of its own subunits. Estradiol is produced by the fetoplacental 
unit and is very important hormone beca~se numerous studies have shown that it can 
modulate placental hormone production (94 )'.. 
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Growth factors, such as colony stimulating factor-l(CSF-1), and insulin-like growth 
I 
factor-I (IGF-1), promotes the trophoblast di(ferentiation into STB (95). On the other hand, 
tumor necrosis factor-alpha (TNF-a) impaits the expression of CGB subunit (54), while 
I 
I 
transforming growth factor-Bl (TGF Bl) inhibits hCG and hPL secretion (56), suggesting 
I 
that these growth factors inhibit STB diff~rentiation. Interestingly, leukemia inhibitory 
I 
factor (LIF) enhances trophoblast fusion but :decreases CGB mRNA levels (55). This study, 
I 
together with a previous report ( 66), suggest;s that distinct signalling pathways are involved 
I 
: 
in cell fusion and CGB expression. 
11.3.3.MicroRNA 
Recent genome-wide analysis of PtiRNA (miRNAome) by miRNA array has 
I 
identified 600 miRNAs in healthy term pla~enta (17). While the function of most of these 
I 
miRNAs is unknown, recent studies have ~hown that miRNAs regulate cell proliferation, 
I 
migration and invasion. For example, rhiR-210, miR-37a, and miR-155 inhibit cell 
proliferation, invasion and migration while!miR-378a-5p, miR-376c and miR-195 had the 
I 
opposite effects. (17-18). In addition, miRNAs have also been implicated in the regulation 
of STB differentiation by t~geting various genes ( 45). It has been recently reported that 
I 
miR-19b and miR-106a directly target aro~atase expression (estrogen synthesis enzyme) 
I 
and impair STB differentiation. MicroRNi;\.-19b also targets human GCMl (hGCMl) to 
I 
I 
inhibit trophoblast differentiation into $TB (47). Similarly, miR-20b also inhibits 
syncytialization (96). 
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IV. Cyclin G2 
I 
Cyclins play a key role in the regufation of cell cycle by activating the cyclin -
I 
dependent kinases (CDKs) enzymes. Mamlnalian cyclins are classified on the basis of 
I 
structural similarity and functional, and regulation expression pattern into twelve different 
I 
I 
types ( cyclins A to I) ( 69). Human cyclin 02 belongs to the cyclin G family of proteins also 
I 
comprised of cyclin G 1 and cyclin I. Thes¢ cyclins are known as unconventional cyclins 
because unlike other cyclins, they do not I form complexes with any cyclin- dependent 
protein kinases and they inhibit cell cycle pr~gression (70). 
Cyclin 02 (CCNG2) is up-regulate~ during growth inhibition or apoptosis. (71 ). 
I 
CCNG2 is quickly degraded through the tlbiquitin-proteasome pathway (72). The short 
half-life of CCNG2 may provide a way for the quiescent cells to re-enter the cell cycle. 
I 
I 
Therefore, increase in cyclin G2 expression ~inhibits the cell cycle progression and maintain 
the cells in a differentiated state (73). 
I 
The up-regulation of cyclin 02 expression at protein and mRNA level has been 
I 
I 
reported in the process of human adipocyte fifferentiation process (70). The mechanism by 
which cyclin G2 induces adipocyte .diffe~entiation is by direct binding to the nuclear 
receptor peroxisome proliferator-activated : receptor gamma (PPARy) and increasing the 
I 
transcriptional activity of PPARy (74). The PPARy is a ligand-activated transcription factor 
and controls the expression of genes which are involved in different physiological 
processes, including adipogenesis and glucose homeostasis (75) 
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Recently, CCNG2 was reported to'. be expressed in human placenta with an 
I 
increased level in mid-gestational stage bd then decreases sharply at term (76). 
I 
Immunohistochemical analysis of CCNG2 in ;placenta revelaed that it is highly expressed in 
I 
term placentae obtained from compromised; pregnancy, such as pre-eclampsia (PE) and 
I 
gestational diabetes mellitus (GDM) as cdmpared to normal gestation placentae (76). 
Although the function of CCNG2 in placentai is unknown, its high expression level suggests 
I 
that it may play a role in placental development (76). 
I 
V. Objectives of the study 
MicroRNAs have been detected in human placenta and recent studies have 
suggested that they play important roles in tegulating placental development and that their 
I 
dysregulation is associated with various! gestational disorders (29). Our lab has 
I 
I 
demonstrated miR-378a-5p promotes trophdblast cell proliferation migration and invasion 
I 
i 
(82). The objective of this study is to furt~er understand the role of miR-378a-5p during 
placental development. Specifically, I exarriined if miR-378a-5p regulates trophoblast cell 
differentiation along the STB pathway andi explored the potential mechanism~ by which 
miR-378a-5p controls STB differentiation. 
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Chapter II. Material and Methods 
11.1 Materials: 
I 
Dulbecco's modified Eagle's medium (DMEM) was purchased from (Hyclone), Ham's 
I 
I 
F12 and Fetal Bovine Serum (Gibco), penic~llin and streptomycin (Life Technologies), 
I 
Trypsin (0.2% Gibco ), Forskolin (Sigma-Aldrich). Bovine Serum Albumin (BSA) 
I 
I (Sigma ), ECL (Millipore ), TRizol Reagent (Life Technologies), M-MuLV Reverse 
I 
Transcriptase ( New England), oligo dT primer (Sigma), SsoFast EvaGreen Supermix 
I 
(Bio-Rad), Dual Luciferase Reporter Assay System (Promega). 
I 
I 
11.2. Be W o cell culture 
Be W o cells, human choriocarcinoma cell line, were purchased from American Type 
I 
Culture Collection (ATCC). Cells were culthred at 37°C in a humidified atmosphere of 
I . 
5% C02 in a 1:1 mixture of DMEM and H~'s F12, and supplemented with 10% heat 
I 
I 
inactivated FBS, 100 IU/ml penicillin and 1 OOµg/ml streptomycin. Cells between 
I 
passage 10 and 15 were used in all the experift1ents. 
11.3. Induction of BeWo cell differentiatio~ with Forskolin 
Syncytialization of BeWo cells was induced! with Forskolin. Forskolin was prepared in 
I 
100% DMSO and added to the medium wit~ the final concentration of 50 µM. Controls 
I 
were treated with the same concentration :of DMSO that serves as the vehicle for 
I 
Forskolin. BeWo cells were treated· with 1or without Forskolin in 1:1 DMEM/F12 
medium, supplemented with 1 %FBS. 
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11.4. Transient transf ection 
Transient transfection of plasmids, miRNA mimics, inhibitors or siRNA were carried out 
I 
using Lipofectamine 2000 or Lipofectami~e RNAiMAX (Invitrogen) following the 
I 
manufacturer's suggested procedures (73). tvficroRNA mimics, inhibitors and siRNA 
were purchased from GenePharma Co. (Shanghai, China). Generation of CCNG2 
I 
expressing plasmid (pcDNA4-CG2-V 5) was reported previously (72). Luciferase 
reporter constructs containing different regidns of the CCNG2 3 'UTR were generated 
I 
by inserting a 3 'URT fragment into the MCS (multiple cloning site) region of pMir 
I 
Report luciferase vector downstream of the quciferase coding gene. Construct 1 contains 
I 
the first predicted site, and construct-2 contains the other three predicted site of miR-
1 
378a-5p. 
I 
11.5. Protein extraction and Immunoblotting (Western blot) 
I 
I 
Cells were washed with cold PBS and cell lysate was prepared usmg 
radioimmunoprecipitation assay (RIPA) butfer (50 mM Tris HCl, 150mM NaCl, 1 % 
Triton X-100, 0.5% deoxycholate, and 1 % $DS) containing protease inhibitor cocktail. 
I 
Cell lysates were centrifuged at 12,000g for 70 minutes at 4°C. Protein concentrations of 
I 
the cell lysate was measured by Bicinchoniruc acid (BCA) method using bovine serum 
I 
albumin as a standard. Equal amount of protein samples (30ug) were subjected to 10% 
SDS-polyacrylamide gel electrophoresis anq transferred onto a polyvinylidene difluoride 
(PVDF, Bio Rad) membrane. The PVDF ~embranes were blocked with 5% milk in 
TBST (lOmM Tris-Cl pH 8.0, 150 mM Na¢1, and 0.05% Tween 20) for 1 hour at room 
21 
temperature and then incubated with primary:1antibodies in the blocking buffer overnight 
I 
i 
at 4 °C. Primary antibodies used were: ahti-E-cadherin (1 :500, Santa Cruz), anti-
1 
I, 
Syncytin-1 (1 :500, Santa Cruz) and anti-GAPDH (1 :5000, Santa Cruz). The membranes 
I 
were washed with TBST and subsequently probed with HRP-conjugated secondary 
antibody at room temperature for 1 hr. Sig~als were detected using ECL according to 
manufacturer's protocol. 
11.6. Immunofluorescence 
I 
Be Wo cells were seeded on the coverslips ih a 12-well plate at the density of 4 x 105 
I 
/well. The next day, cells were treated with/ 50µM Forskolin or transiently transfected 
i 
I 
with miR-378a-5p/anti-miR-378a-5p at different time points. Cells were fixed in 
I 
I 
methanol (-20°C) for 10 minutes and washed with PBS (x 3). Non-specific bindings 
I 
I 
were blocked with 3% BSA in PBS for 1 h~ur and then incubated with primary mouse 
I 
monoclonal anti-E-cadherin antibody (1 :50 ~ilution in 3% BSA in PBS) overnight at 4 
°C. The coverslips were washed with PBS~ buffer (x3) and incubated with goat anti-
mouse secondary antibody, Alexa Fluor 594, (1 :300 dilution in 3% BSA in PBS, Life 
I 
Technologies) at room temperature for 1 hr. ;cell nuclei were counterstained with DAPI 
I 
I (1: 1000, Sigma) for 5 minutes._ Finally, 1 coverslips were washed and mounted. 
I 
Coverslips were examined with the inverted! fluorescence microscope and photographed 
using a Nikon camera and Simple PCI sofu}'are. Cell fusion was analyzed in randomly 
I 
20 selected field of each condition in triplic.ates and scored when ~ 3 nuclei shared the 
22 
same cytoplasm. The quantification of cell-cbll fusion was expressed in percentage and 
calculated as the ratio of number of nuclei irt the syncytia to the total number of nuclei 
I 
counted in the field. 
11.7. RNA extraction and RT-qPCR 
Total RNA was extracted from the cultur~d cells and isolated with Trizol Reagent 
according to manufacturer's instructions. 11wo microgram of total RNA was used to 
! 
I 
synthesize first stand cDNA by M-MuL V Reverse Transcriptase. RT-qPCR was carried 
I 
I 
out using gene specific primers (Table 1) and SsoFast EvaGreen Supermix. The 
expression levels of mRNA were normalizFd to GAPDH. The qPCR reactions were 
carried out using primer sets indicated in T~ble 1, with initial denaturation step at 95°C 
I 
for 1 minute and followed by 40 cycles of 2o seconds at 95°C, 30 seconds at 60°C and 
30 seconds at 72°C. Ct values were used 1 to calculate the expression levels of gene 
expression by the standard ~~Ct method. 
11.8. miR-378a-5p detection by TaqMan a!ssay 
Total RNA was isolated with Trizol reagent from the cultured cells with a slight 
modification in the protocol as previous!~ reported. Specifically, the precipitation of 
RNA was carried out at -20°C overnight 1to enrich the small RNA population (123). 
Both reverse transcription and qPCR were carried out according to the 
manufacturer's instructions. Reverse Tt!anscription was carried out by TaqMan 
23 
Table 1 Primers used for qPCR: Syncytin-1, Syncytin-2, ALPP,. LGALS13 and CGB 
with their forward and reverse primers. 1 
Primer sets 
Syncytin-1 
Sense 
Anti sense 
Syncytin-2 
Sense 
Anti sense 
ALPP 
Sense 
Anti sense 
LGALS13 
Sense 
Anti sense 
CGB 
Sense 
Anti sense 
Sequence 
TCATATCTAAGCCCCGCAAC 
TGATCTTGCAAGGTGACCAG 
TCG GAT ACC TTC GCT AGT GC 
GTATTCCGGAGCTQAGGTTG 
ACGGGAAGAATCTQGTGCAG 
GTGGAGTCTCGGTQGATCT 
ATTGCCTTCCGTTTCCGAGT 
TTTGCCATCCTCAA.AGGGCA 
I 
CCGTCAACACCACOATCTGT 
ATTGACAGCTGAGAGCCACG 
I 
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microRNA Reverse Transcription Kit and ~ubsequently qPCR was performed for the 
I 
detection of microRNAs. U6 was used as a 1housekeeping gene and amplified for each 
I 
I 
sample. The relative expression of miR-37S
1
a-5p was determined using standard ~~Ct 
method. 
11.9. Luciferase assay 
BeWo cells were seeded in 12-well plates iat the density of 8xl05 cells/well and co-
1 
'1 
transfected with 25 nM of negative control; or miR-378a-5p mimics, 0.175 µg pMIR-
Report-CCNG2 3 'UTR plasmids, and 0.1 : µg pRL-TK internal control (encoding 
Renilla luciferase) plasmids. Five hours ~fter transfection, cells were recovered in 
i 
DMEM/F 12 for another 19 hours. Twenty;-four hour of post transfection, luciferase 
I 
activities were measured using the Dual Lupiferase Reporter Assay System (Promega) 
according to the manufacturer's instructions.: 
11.10. Statistical analysis 
I 
All the experiments were done at least thrre times with triplicate in each group. The 
results are expressed as mean ± SEM. Statistical analysis was performed using Sigma 
Stat software. The experiments with multiple groups were analyzed by one-way ·analysis 
of variance, with Student-Newman-Keuls post hoc test to determine the statistical 
I 
significant differences among the individ'1al groups. Student's t-test was used for 
comparison between two groups. P<0.05 wa~ considered statistically significant. 
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Chapter III. Results 
I 
111.1. Forskolin induces syncytiotrophoblast differentiation 
I 
The choriocarcinoma Be Wo cell line 1is the most extensively used in vitro model to 
I 
I 
study syncytialization because of the higµ degree of similarity to normal placental 
I 
trophoblast (66). It is well documented th~t activation of the cAMP pathway, such as 
I 
addition of cAMP analogue 8-bromo-cAMP or the activator of adenylate cyclase Forskolin, 
I 
induces Be Wo cell fusion and STB marker; gene expression (98). In order to establish a 
I 
I 
positive control for our differentiation assays, Be W o cells were treated with control and 
different concentrations of Forskolin (25, µM, 50 µM and 100 µM) for 48 hours. 
I 
Immunofluorescent staining with an E-cad~erin revealed that Forskolin strongly induced 
cell fusion (Fig. 4). Quantification of the nillnber of cells with 3 or more nuclei indicated 
that 50 µM of Forskolin is the most effecti~e dose in inducing cell fusion. Therefore, this 
I 
dose ofForskolin was selected and used for further experiments as a positive control. 
I 
To determine the time course: effect of Forskolin BeWo cells were treated with 
I 
DMSO (control) or 50 µM dose ofForskolin: for 24, 48 and 72 hours. Western blot using an 
anti-E-cadherin antibody revealed that E-cadherin levels were decreased significantly by 
I 
Forskolin at 48 and 72 hours after treatmenf (Fig. SA). Forskolin also induced the mRNA 
level of Syncytin-1, a marker gene of STB, at the 48 and 72 hour time points (Fig. 5B). 
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Fig. 4o For©kollill11 RndURc<es impllD.otbhM~ ~eftD fmiion. A) Representative pictures show BeWo 
cells treated with vehicle only (DMSO) and Forskolin (50 µM) for 48 hours and 
immunotluorescence was performed. Cell membranes were stained with anti-E-cadherin (red) 
and cell nuclei were stained with DAPI (blue). Merged pictures were shown in the right panel 
*,fused nuclei in the merged picture were marked with stars. B). The Immunofluorescence 
was performed on cells treated with DMSO or different concentrations of Forskolin (25, 50 
and l OOµM) for 48 hours and fused nuclei were counted. The graph shows that 50 µM is the 
most effective dose in inducing cell fusion. ,***P<0.001 vs. DMSO control. Data represent 
mean ± SEM of 3 experiments. 
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Fig. 5. Forskolin decreases E-cadherin protein expression and increased Syncytin-1 
mRNA levels. Cells were treated with 1:DMSO as the control or Forskolin for 24, 48 and 
I 
72h. A). A representative blot of E-caqherin and GAPDH and a summary graph from 3 
experiments showing that F orskolin inhibited E-cadherin expression at 48 and 72h after 
treatment.,***, p:S0.001 vs. control. B). RT-qPCR of syncytin-1 from BeWo cells treated 
with DMSO or Forskolin for 24 to 72 ~ours. Forskolin significantly increased syncytin-1 
m.RNA levels at 48 and 72h after treatment. ***, p:S0.001 vs. DMSO. control. Data 
represent mean ± SEM of 3 experiments. 
28 
111.2. miR-378a-5p is suppressed during Forskolin-induced syncytialization 
To investigate the potential involvement of miRNAs m STB differentiation, I 
determined the level of several miRNAs in BeWo cells treated with Forskolin and DMSO 
controls for 24, 48 and 72 hours. Real-time PCR was used to quantify miRNA levels. 
There was a significant decrease in the endogenous level of miR-378a-5p in the Forskolin-
1 
treated group at 48 and 72 hours, as compared to its respective control (Fig. 6). 
111.3. miR-378a-5p inhibits syncytiofrophoblast differentiation 
The down-regulation of miR-378a-5~ during Forskolin-induced STB differentiation 
I 
suggests that it may inhibit syncytializati~n. To test this hypothesis, several sets of 
I 
I 
I 
experiments were performed to determine the effect of miR-378a-5p overexpression on 
I 
morphological and biochemical differentiatipn of STB. Be Wo cells were transfected with 
I 
different concentrations (50nM, lOOnM and 200nM) of miR-378a-5p, a non-targeting 
negative control (NC) or with a mock transfection for 72 hours and cell fusion was assessed 
by immunofluorescence. As shown in Fig. 7('.., transfection with miR-378a-5p resulted in a 
decrease in cell fusion. When the percentage of fused Be W o cells was calculated by 
I 
counting the number of cells with 3 or more :nuclei (Fig. 7B) or 2 or more nuclei (Fig. 7C), 
I 
a significant decrease in cell fusion was observed in cells transfected with 100 or 200 nM 
I 
miR-378a-5p, as compared to their correspo*ding NC and Mock controls. 
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experiments). 
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Fig. 7. miR-378a-5p inhibits cell fusion. A) Representative pictures of immunofluorescence 
staining of E-cadherin in BeWo cells trartsfected without (mock) or with negative control 
(NC) or miR-378a-5p (200 nM). Membratje was stained with anti E-cadherin antibody (red) 
and nuclei were stained with DAPI (blue).1 Merged pictures (fused nuclei marked with stars) 
are shown in the right panel. B) A summaty graph showing the percentage of cells with 3 or 
more nuclei in cells transfected with diffefent concentration of miR-378a-5p or NS for 72h. 
C) A summary graph showing the percentage of cells with 2 or more nuclei. 
Data represent mean ± SEM (n=3 experim~nts ). 
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To further evaluate the role of miR-378a-5p in STB differentiation, RT-qPCR was 
I 
used to analyze the mRNA level of sever~l STB marker genes, including Syncytin-1, 
I 
Syncytin-2, ALPP and LGALS13. BeWo cells transfected with 100 and 200nM of miR-
1 
378a-5p showed a statistically signific;ant decrease in mRNA level of Syncytin-1 (Fig. 8B 
and 8C). Transfection of 200 nM miR-378~-5p also decreased Syncytin-2 mRNA levels 
(Fig. 9C). However, there was no significapt difference between the control groups and 
those transfected with a lower dose of miR-378a-5p (Fig. 9A, B). Similarly, miR-378a-5p 
also inhibited the expression of ALPP (Fig. :1 OC) and LGALS 13 (Fig. 11 C) at the 200nM 
concentration. Overall, these results showed :that miR-378a-5p downregulated STB marker 
gene expression in a concentration- dependent manner. 
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111.4. miR-378-Sp inhibits Forskolin-induced syncytiotrophoblast differentiation 
i 
To understand the role of miR-378a~5p in STB differentiation, BeWo cells were 
transfected with miR-378a-5p (200nM) or a: negative control (NC) for 24 hours and then 
cells were treated with DMSO (contn~l) or Forskolin (50uM) for 48 hours. 
I 
I 
Immunofluorescent studies showed that miR-378a-5p reduced cell fusion not only under 
• I 
basal condition, but also in Forskolin-treated 
1
cells (Fig. 12). 
I 
E-cadherin is lost during cell fusiorn Therefore, a decrease in E-cadherin protein 
I 
expression is often used as an indicator of STB differentiation (101). To further confirm the 
inhibitory effect of miR-378a-5p in ST~ differentiation, Western blot analysis was 
conducted on cell lysate prepared from cel~s transfected with miR-378a-5p (200nM) and 
negative control for 24 hours and treated with DMSO and Forskolin for 48 hr. Western 
blotting using an anti-E-cadherin and a GAPDH antibody revealed that miR-378a-5p 
increased E-cadherin protein levels and re~ersed the inhibitory effect of Forskolin on E-
cadherin expression (Fig. 13). 
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Figa Jl2. mnR-378~-Sp furnlhlfibut§ Fonlk.ooo-induced cell fusnon. BeWo cells were 
transfected with miR-378a-5p (200n.M) or a negative control (NC) for 24 hours and then 
treated with either DMSO or Forskolin (50 µM) for 48h. A) Representative pictures of 
immuno:fluorescence staining using anti;E-cadherin antibody (red for membrane) and 
DAPI (blue for nuclei). Fused nuclei were marked with stars. B) Quantified results show 
that miR-378a-5p decreased basal and F:orskolin-induced cell fusion. Different letters 
above bars denote statistical significance. Data represent mean ± SEM of 3 experiments. 
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I 
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111.5. Anti-miR-378a-5p induces syn~ytiotrophoblast differentiation 
Anti-microRNAs can reduce the endogenous level of a miRNA and result in an 
increase in target gene expression (35). To confirm the physiological significance of miR-
378a-5p in regulating STB differentiation, I investigated the effect of anti-miR-378a-5p on 
STB differentiation. First, BeWo cells were1transiently transfected with anti-miR-378a-5p 
(200nM) or negative control (NC) or without: any oligonucleotide (mock). At 72 hours after 
I 
transfection, morphological differentiation was analyzed by immunofluorescence. 
I 
I 
Compared to mock transfection or NC, anti-rhiR-378a-5p significantly increased cell fusion 
I 
as indicated by the number of cells with 3 ;or more nuclei (Fig. 14). Second, RT-qPCR 
analysis showed that anti-miR-378a-5p increased the mRNA level of STB marker genes, 
I 
Syncytin-1, -2, ALPP and LGALS13 (Fig. 115) Third, in immunoblot analysis, anti-miR-
378a-5p decreased E-cadherin but increased1Syncytin-l protein levels and these effects are 
opposite to miR-3 78a-5p overexpression (Fig. 16). 
I 
Fusion of CTB into STB is also associated with an increase in the expression of 
CGB gene (100). I, therefore, determined th~ effect of miR-378a-5p and anti-miR-378a-5p 
on CGB mRNA expression. BeWo cells were transiently transfected with 200nM 
concentration of miR-378a-5p or anti-rniR-378a-5p, together with mock and corresponding 
! 
controls. Total RNA was extracted and mRNA level of CGB was determined by RT-qPCR. 
Figure 17 shows that CGB levels were decreased significantly in cells transfected with 
miR-378a-5p. On the other hand, cells transfected with antimiR-378a-5p had an increase in 
CGB mRNA levels. 
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Fig. 17. miR-378a-5p and anti-miR-378a-5p exert opposite effects on the expression 
of chorionic gonadotropin B-subunit (CGB). BeWo cells were transiently transfected 
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111.6. miR-378a-5p targets cyclin G2 , 
To explore the mechanisms by whic.h miR-378a-5p inhibits the differentiation of 
STB, bioinformatic tools (FindTar3) was used to examine the predicted target genes of 
I 
miR-378a-5p. It was found that miR-378a-5p has five potential complementary binding 
I 
sites at the 3 'UTR of CCNG2 (Fig. 18). Since CCNG2 is known to induce adipocyte 
I 
differentiation (70) and its expression in the placenta has been recently reported (76), we 
hypothesize that CCNG2 may promote STB: differentiation and may be down-regulated by 
miR-378a-5p. To test this possibility, l~ciferase reporter assay was first performed. 
CCNG2 3' UTR is almost 4 kb long and has five predicted target sites of miR-378a-5p, 
I 
spanning almost the entire 3'UTR (Fig. 18)J Two CCNG2 3' UTR fragments (CCNG2 3' 
UTR-1 and CCNG2 3' UTR-2) were cloned into the pMIR-REPORT vector, downstream 
I 
of the luciferase coding sequence (Fig. 19 A~, by a research associate and a PhD student in 
I 
the lab, respectively. BeWo cells were co-transfected with a control reporter (without 
3'UTR) or one of the two constructs of CC;NG2 3' UTR construct and miR-378a-5p or its 
NC or mock controls. Luciferase assays were performed at 24h after transfection. 
I 
MicroRNA-378a-5p significantly decrease? the luciferase activity of CCNG2 3'UTR-1 
construct, which contains the first predicte~ site of miR-378a-5p (Fig. 19B). A decrease in 
luciferase activity by miR-378a-5p was a)so observed in the cells transfected with the 
CCNG2 3 'UTR-2 construct; however, the~ difference is not statistically significant (Fig. 
19B). 
46 
hsa-miR-378a-5p 
CCNG2 (74-97) 
hsa-miR-378a-5p 
CCNG2 (1593-1610) 
hsa-miR-378a-5p 
CCNG2 (2525-2548) 
hsa-miR-378a-5p 
CCNG2 (2810-2828) 
hsa-miR-378a-5p 
CCNG2 (3141-3164) 
3,' 
5' 
s~ UGUGUCCOGGACCU 
I 
S' 
$' 
3' UGOGUCCUG-G-ACCUdll§fr!aC 5' 
id> ilt' : I I I * I * I * H * ·* *RBll•11 I 
s• GAGTAGGTCACGCAC~G 3' 
; 3 • uGuGuccuGGAC:GUcfif!!wffpc s ' ; 
"1111*11 I*·••• 1 flaliillllft 
:.s' I'CACA-GAc~-·-~AA····G 3' 
! 
i3' UGUGUCCUGGAC---cucl@Mc 5' 
U*UU I 11 I I ******l.11111"" 
S' TTTAATTACCTGTCACAUijfjBiiT 3' 
Fig 18. Predicted miR-378a-5p targeting sites on CCNG2 3' UTR. miR-378a-
5p has five potential target sites on CCNG2 3'UTR, as predicted by Findtar3. 
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To further confirm that miR-378a-5p regulates CCNG2, BeWo cells were 
transiently transfected with 200nM concentration of miR-378a-5p or anti-miR-378a-5p, or 
their corresponding controls, total RNA wa~ extracted at 72h after transfection and mRNA 
I 
level of CCNG2 was determined by RT-qFCR. Figure 20A shows that CCNG2 mRNA 
levels were significantly lower in cells transfected with miR-378a-5p than in control cells. 
I 
I 
Conversely, cells transfected with anti-miR-378a-5p have significantly higher CCNG2 
mRNA levels than control cells (Fig. 20B). 
Finally, I determined if CCNG2 'regulates STB differentiation. Cells were 
I 
transfected with control plasmid vector (E~) or plasmid expressing CCNG2 (CCNG2). 
I 
Cell lysates were prepared at 24 hours after1 CCNG2 expression and Western blot analyses 
I 
were performed using an anti-E-cadherin and anti-syncytin-1 antibodies. Overexpression of 
CCNG2 resulted in a significant inhibition of E-cadherin but a strong induction of 
Syncytin-1 protein levels (Fig. 21A). On the other hand, knockdown of CCNG2 expression 
I 
using a siRNA-mediated gene silencing approach increased E-cadherin and decreased 
Syncytin-1 protein levels (Fig. 21B). 
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Fig. 21. CCNG2 induces syncytiotrophoblast differentiation. A). Be Wo cells were 
transfected with control plasmid vector (EV) or plasmid expressing CCNG2 (CCNG2). Cell 
lysates were prepared at 24 h after transfection and subjected to immunoblotting using anti-E-
cadherin and anti-syncytin-1 antibody. Representative immunoblots and graphs depicting the 
densitometric intensities of E-cadherin an~ syncytin-1 levels are shown. Transfection of 
CCNG2 resulted in a decrease in E-cadh~rin and an increase in syncytin-1 protein levels. 
*p<0.05 vs. corresponding empty vector. Data are mean± SEM of 3 replicate wells in one 
experiment. B) Silencing of CCNG2 expression increased E-cadherin levels. Cells were 
transfected without (mock) or with a si~A targeting CCNG2 (siCCNG2) or its negative 
control (NC). Cell lysates were prepared at !48h after transfection. 
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Chapter IV. Discussion 
Expression of miRNAs in placenta and their dysregulation in gestational disorders 
suggest that they are important regulators1 of placental development and function (29). 
Recently, we have demonstrated that miR-378a-5p promotes trophoblast cell survival, 
I 
I 
proliferation, migration and invasion by targeting Nodal (82). Moreover, in human 
I 
placenta, miR-378a-5p is expressed thro~ghout gestation and its levels were lower in 
preeclamptic patients than the healthy cqntrols (82), suggesting that it has important 
regulatory functions in placenta and its : abnormal expression may contribute to the 
development of pregnancy associated disbrders, such as preeclampsia. This study was 
carried out to further investigate the role ·pf miR-378a-5p during placental development, 
specifically, to examine the potential role of miR-378a-5p in trophoblast cell differentiation 
into the STB pathway. I demonstrated that miR-378a-5p inhibits the STB differentiation 
and identified cyclin G2 (CCNG2) as a target gene of miR-378a-5p. These findings further 
support the notion that miR-378a-5p is an important regulator of human placental 
development. In addition, this study provides the first evidence that CCNG2 regulates 
trophoblast cell differentiation. 
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IV .1. miR-378a-5p is an inhibitor of syncytiotrophoblast differentiation 
Be Wo cells have been used extensi:vely to study trophoblast cell differentiation 
along the STB pathway (65,121). In the pre,sent study, I used this cell line to examine the 
role of miR-378a-5p in regulating the differentiation of CTB into STB. During STB 
differentiation, CTB. cells fuse to form multinucleated STB cells and this is accompanied 
by expression of STB specific genes, sucH ·as Syncytin-1, Syncytin-2, ALPP, hCG and 
I 
LGALS13 (57,61,63,64). Therefore, STB differentiation can be studied by morphological 
I 
I 
and biochemical approaches. Before proceeding with differentiation assays, I first tested the 
I 
dose-dependent and time-course effect of F orskolin, which is well documented to induce 
I 
I 
STB differentiation, (66, 42, 98) to establis~ a positive control in our assays. 
To explore the potential involveme~t of miRNAs in regulating STB differentiation, 
I first examined several miRNA levels during Forskolin-induced STB differentiation. I 
found that miR-378a-5p levels were stronglr inhibited by Forskolin treatment. The specific 
factor(s) which downregulates the miR-37~a-5p level remains to be identified. It is well 
I 
known that activation of adenylate cyclase by Forskolin results in the accumulation of 
I 
i 
cAMP (98) which activates protein kinase A (PKA) (104). PKA could activate 
transcription factors that are involved in the transcription of miR-378a-5p gene. A 
potential transcription factor that may regulate miR-378a-5p is peroxisome proliferator-
1 
activated receptor 'Y (PP ARy) which: is involved in cell differentiation, development and 
metabolism, including adipogenesis and g~ucose homeostasis (75). A recent study in mouse 
adipocytes has identified an inhibitory effect of PPARy on the expression of miR-378, 
which is a homologue of human miR-3?8a-5p (Fig. 22A)~ In human trophoblast cells, 
I 
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PPARy promotes the differentiation of STB (117, 119). Therefore, it is possible that 
PPARy is involved in the Forskolin-inhibhed miR-378a-5p expression. This can be 
investigated in future studies. 
Downregulation of miR-378a-5p dµring Forskolin-induced STB differentiation 
suggests that miR-378a-5p may have an inhibitory effect on the differentiation of CTB to 
STB. To test this possibility, I performed several functional assays and examined the effect 
I 
of miR-378a-5p overexpression on morphological and biochemical differentiation of STB. 
I 
First, immunofluorescence results showed that transfection of a miR-378a-5p mimic 
significantly reduced the number of cells that have multiple nuclei, indicating that miR-
1 
378a-5p inhibits cell fusion. Then, RT-qPCR analysis of Syncytin-1, Syncytin-2, CGB, 
ALPP and LGALS13 showed a significant downregulation in STB marker gene expression 
I 
in a concentration dependent manner. Firtally, miR-378a-5p increased E-cadherin and 
I 
decreased Syncytin-1 p~otein expression l~vels. It is well documented that E-cadherin 
I 
levels are decreased during STB formation (106, 107). Moreover, Syncytin-1, Syncytin-2, 
I 
I 
ALPP and LGALS13 have been shown to 1be expressed in STB. Therefore, a decrease in 
I 
the expression of these genes provides a,dditional evidences that miR-378a-5p has an 
inhibitory role in STB differentiation. 
I also evaluated if miR-378a-5p cou.ld block Forskolin-induced STB differentiation. 
E-cadherin immunostaining results showed that miR-378a-5p reduced cell fusion not only 
I 
under basal condition but also in Forskolin.i.treated cells. In concordance with these results, 
I 
Western blot analysis revealed that miR...!378a-5p increased E-cadherin protein in both 
, I 
control cells and cells treated with :For*olin. The miR-378a-5p increased E-cadherin 
protein levels and reversed the inhibitory; effect of Forskolin on E-cadherin expression. 
I 
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These results confirm that miR-378a-5p plays an inhibitory role in the STB differentiation 
pathway. 
The physiological role of miR-378a-5p in regulating STB differentiation is further 
supported by loss-of-function studies. I used antisense oligonucleotide (anti-miR-378a-5p) 
to inhibit the endogenous miR-378a-5p. Fir~t, I found that anti-miR-378a-5p significantly 
increased the number of cells with multiple' nuclei. Then, RT-qPCR analysis showed that 
anti-miR-378a-5p significantly increased the' mRNA levels of STB marker genes, Syncytin-
I 
1, Syncyin-2, CGB, ALPP and LGALSl~. Finally, E-cadherin immunostaining results 
showed anti-miR-378a-5p decreased E-cadherin but increased Syncytin-1 protein levels. 
I 
I 
Anti-miRNAs are modified antisense oligonucleotides that have partially or fully 
I 
I 
complementary sequence of mature mi$A. They inhibit endogenous miRNAs by 
inducing their degradation and release targ~t gene repression by the miRNAs (23). Thus, 
I 
these results suggest that trophoblast cells can be induced to differentiate into the STB 
I 
pathway by inhibiting endogenous miR-378a-5p. 
I 
Collectively, data obtained from this study strongly suggest that miR-378a-5p 
inhibits STB differentiation. We have previously demonstrated that miR-378a-5p enhanced 
trophoblast cell migration and invasion. It is therefore possible that miR-378a-5p promotes 
I 
trophoblast cell differentiation into the'. invasive EVT pathway but prevents their 
I 
differentiation into the STB pathway. ~ More studies are required, especially using 
I 
I 
trophoblast cells prepared from healthy human placenta, to test this hypothesis. 
I 
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IV.2. Target genes of miR-378a-5p 
This study identifies CCNG2 as a target gene of miR-378a-5p. CCNG2 transcript 
I 
has a 4-kb 3' UTR that contains predicted binding sites for many miRNAs. Interestingly, 5 
potential binding sites have been predicted' for miR-378a-5p. Several lines of evidence 
suggest that CCNG2 is a true target of miR-378a-5p. First, miR-378a-5p decreased the 
luciferase activity of CCNG2 3 'UTR-1 con~truct. Second, mRNA levels of CCNG2 were 
lower in miR-378a-5p overexpressed cells ~ut higher in the presence of anti-miR-378a-5p. 
I 
Finally, knockdown of CCNG2 using sil{NA mimicked the effect of miR-378a-5p in 
trophoblast cell differentiation. Addition~! studies, especially luciferase assays using 
I 
constructs that contain mutated binding sequence of miR-378a-5p and Western blotting to 
I 
measure CCNG2 protein levels, will further confirm that CCNG2 is a target gene of miR-
378a-5p. 
It is well established that a miRNA can target many genes (35). Several of the 
reported target genes of miR-378a-5p, such as Nodal (82), aromatase (83), and IGFlR 
(126), may be involved in STB differentiation. 
Nodal is a member of transforming growth factor beta (TGF- ~) superfamily and 
plays important roles during embryonic development (110), regulates placental 
development m mouse and trophoblast differentiation (111), inhibits trophoblast 
proliferation, migration, and invasion, ~d induce apoptosis (112,113) and promotes 
trophoblast cell survival, migration and in~asion. We have already demonstrated that Nodal 
is a target gene of miR-378a-5p and regulates trophoblast cell survival, invasion and 
56 
migration (82). Moreover, it has recently reported that Nodal inhibits E-cadherin 
expression in BeWo cells (114). Future studies will investigate if Nodal promotes STB 
differentiation and if miR-378a-5p inhibits t~e STB differentiation by targeting Nodal. 
Aromatase has been identified as a target gene of miR-378 in porcine follicular cells 
I (83). Aromatase P450 (P450 arom) is a product of CYP19 gene which catalyzes the 
conversion of C 19 steroids to estrogens and syncytiotrophoblast differentiation is 
associated with marked induction of CYP 19 gene expression and aromatase activity (120, 
i 
124,128) (116). In addition, miR-378a-5p 1 targets insulin like growth factor-1 receptor 
I 
I 
(IGFlR) expression (123). IGFs are the stimulator of tissue growth and regulate the 
differentiation, mitogenesis and survival of target cells. IGFs exert their effects by binding 
to IGFlR. The IGFlRs enhance trophoblast proliferation and differentiation and rescue 
trophoblast from apoptosis (127). IGFlR expression is increased in BeWo cells during their 
differentiation into STB, suggesting a role ofIGFlR in STB differentiation (103). 
Other than these known targets, database mining also revealed that miR-378a-5p 
has a potential targeting site on hGCMl 3'UTR (Fig. 22B). GCMl is a placenta-specific 
I 
transcriptional factor and is required for placental development (47, 103). It is activated by 
I 
the PK.A pathway and promotes STB fonpation by activating the syncytin protein gene 
expression (104 ). It has been reported that overexpression of GCMl enhanced the syncytin 
I 
gene expression and cell fusion in BeWo cells (103). In addition, hGCMl regulates the 
I 
aromatase (hCYP19I) and CG~ (47). Finally, GCMl deficient mouse embryos failed to 
I 
form STB (122). It is recently reported 'that GCMl is a target gene of miR-19b and 
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overexpression of miR-19b mimics result in decrease syncytium formation (47). The 
possibility that miR-378a-5p suppresses GGMl to inhibit trophoblast cell differentiation 
into STB will be investigated in future. 
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A. 
B. 
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Figure 22. Comparison of human miR-378a-5p with mouse mature sequence 
of miR-378a-5p and GCM-13'UTR. A.) Mouse mature sequence ofmir-378a-5p 
is a homologue of human miR-378a-5p. ~B). miR-378a-5p has a potential target site 
on GCM-1 3' UTR, as predicted by Findtar3. 
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I 
IV.3. Cyclin G2 induces syncytiotrophoblast cell differention 
CCNG2 is an unconventional cyclin that inhibits cell cycle progression (69-71). It is 
I 
expressed in trophoblast cells, including STB, however, its role in human placenta has not 
. I 
been reported. In this study, I provided initial evidence that CCNG2 induces trophoblast 
I 
differentiation along the STB pathway. BeWo cells transiently transfected with a plasmid 
I 
containing CCNG2 coding sequence showed a decrease in E-cadherin and increase in 
syncytin-1 protein levels. On the other hatj.d, knockdown of CCNG2 expression using a 
siRNA-mediated gene silencing approach :resulted in an increase in E-cadherin and a 
I 
decrease in syncytin-1 protein levels. The results suggest that CCNG2 promotes STB 
I 
differentiation. However, more experiments, have to be done in future to further understand 
I 
the role of CCNG2 in STB differentiation. Immunofluorescence and quantification of 
syncytialization markers such as syncytin~l, syncytin-2; ALPP, h~G and LGALS13 in 
CCNG2 overexpressed and siRNA CCNG7 transfected cells can be further determined in 
future studies. Although, results from this study suggest that CCNG2 plays a role in STB 
differentiation, the mechanism by which CCNG2 regulates STB differentiation is yet to be 
explored. 
A recent study demonstrated that CCNG2 interacts with PPARy to induce 
adipocyte differentiation (74). It is reported that PPARy deficiency interferes with 
trophoblast differentiation and vascularization of placenta (117). PPARy signaling 
I 
pathways play important roles in development and function of placenta (118). Interestingly, 
PPARy was detected in STB and it increa~es the ~-hCG transcripts levels and secretion of 
I 
hCG, with the further induction of syncytiotrophoblast hormones such as human placental 
I 
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lactogen, human placental GH, and leptin (1 '.19). The possibility of CCNG2, acting as a co-
activator of PPARy to promote STB differentiation will be investigated in future. 
I 
I 
Taken together this study provides the first evidence that CCNG2 regulates 
I 
trophoblast differentiation and miR-378a-5p is an important regulator of human placental 
I 
development. 
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Figure 23. Working model of miR-378a-
1
5p in syncytiotrophoblast differentiation .. 
miR-378a-5p is down-regulated during cAMP-induced STB differentiation. miR-378a-
5p inhibits cell fusion and STB marker ge~e expression. Cyclin G2, a gene targeted by 
miR-378a-5p, promotes STB differentiation. Several other potential or confirmed 
I 
target genes of miR-378a-5p, such as GCMl, aromatase, Nodal, and IGFlR, may also 
promote STB differentiation. It is possible that miR-378a-5p inhibits STB 
differentiation by down-regulating the expression of these genes. 
I 
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V. Summary and Future Directions 
1 
The major findings of this study are: 
1. miR-378a-5p is a negative regulator of sy~cytiotrophoblast differentiation 
In this study, I examined the role of miR-378a-5p in the regulation of trophoblast 
cell differentiation along the STB pathway. I identified that miR-378a-5p was strongly 
inhibited during Forskolin-induced STB differentiation. Subsequently, I performed several 
functional assays to determine the effect o~ miR-378a-5p overexpression and inhibition in 
• I 
STB differentiation. First, immunofluorescence results showed that transfection of a miR-
378a-5p mimic reduced the numQer of cells that have multiple nuclei, indicating that miR-
378a-5p inhibits cell fusion. Then, RT-qPCR analysis showed that miR-378a-5p 
downregulated STB marker gene expression. Furthermore, Western blotting revealed that 
I • 
miR-378a-5p increased E-cadherin and decreased syncytin-1 protein levels. On the other 
hand, inhibiting endogenous miR-378a-5p µsing an antisense oligonucleotide resulted in an 
I 
I 
increase in STB differentiation. It was foupd that anti-miR-378a-5p increased cell fusion, 
induced STB marker gene expression anq decreased E-cadherin levels. Taken together, 
these findings demonstrate that miR-378a-5p is a negative regulator of trophoblast 
differentiation into the STB pathway. 
We have previously demonstrat~d that miR-378a-5p promotes cell survival, 
migration and invasion. The present study provides novel evidence that miR-378a-5p 
inhibits the STB differentiation. Therefore, it is possible that a physiological role of miR-
63 
378a-5p in placental development is to dire.ct the trophoblast cells into the EVT pathway 
while limiting their ability to differentiate into the STB pathway. This can be further tested 
in future studies by using trophoblast cells from healthy placenta. 
2. Cyclin G2 is a target gene of miR-378a-5p 
Using Bioinformatic tools, luciferase reporter assay, and RT-qPCR, I identified 
CCNG2 as a novel target of miR-378a-5p. ~ioinformatic analysis revealed that miR-378a-
5p has five potential complementary bindillg sites at the 3 'UTR of CCNG2. First, miR-
378a-5p decreased the luciferase activity of CCNG2 3'UTR-1 construct (contains the first 
potential binding site). Then, overexpression of miR-378a-5p showed decrease in mRNA 
levels of CCNG2. Conversely, increase in mRNA levels of CCNG2 was found in cells 
I 
transfected with anti-miR-378a-5p. Finally, !knockdown of CCNG2 using siRNA mimicked 
the effect of miR-378a-5p, while overexptession of CCNG2 had the opposite effects as 
miR-378a-5p, on E-cadherin and Syncytiq-1 expression. These results strongly suggest 
that CCNG2 is a target gene of miR-378a-Sp. However, additional studies are required to 
I 
I 
confirm which binding site(s) interacts with miR-378a-5p. Luciferase assays can be 
conducted using constructs that contain mu~ated binding sites of miR-378a-5p. In addition, 
endogenous levels of CCNG2 following miR-378a-5p transfection will be determined by 
W estem blotting. 
To determine if miR-378a-5p inhi~its STB differentiation by down-regulating, at 
least in part, CCNG2 expression, several'. "rescue experiment" can be performed. First, 
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miR-378a-5p can be co-transfected with a CCNG2-expressing plasmid to test if 
overexpression of CCNG2 will reverse the inhibitory effect of miR-378a-5p. Second, cells 
can be co-transfected with anti-miR-378a-5p and CCNG2 siRNA to examine if silencing of 
CCNG2 expression can prevent anti-miR-3 78a-5p to induce STB differentiation. 
It is well established that a miRNA can target many genes (35) and it is highly 
possible that all of the observed trends are not due to CCNG2 alone. Several confirmed or 
predicted targets of miR-378a-5p, such as Nodal, aromatase, hGCMl, and IGFIR, have 
been shown or suggested to play a role in STB differentiation. Therefore, their 
involvement in miR-378a-5p-regulated STB differentiation will be explored in future 
studies. 
3. Cyclin 02 induces syncytiotrophoblast trophoblast differentiation 
Although CCNG2 has been detecte~ in human placenta, its role during placental 
development is unknown. In this study, I Provided initial evidence that CCNG2 induces 
trophoblast differentiation along the STB pathway. BeWo cells transfected with CCNG2 
showed a decrease in E-cadherin and increase in syncytin-1 protein levels. On the other 
hand, knockdown of CCNG2 expression showed an increase in E-cadherin and a decrease 
in syncytin-1 protein levels suggesting that CCNG2 plays a role in STB differentiation. 
More studies are required to further cpnfirm the role of CCNG2 in trophoblast 
differentiation. Specifically, the effect of CCNG2 on cell fusion and STB marker gene 
expression should be determined. 
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The mechanism by which CCNG2 regulates STB differentiation is yet to be 
determined. A recent study demonstrates that CCNG2 interacts with PPARy to induce 
adipocyte differentiation (74). Since PPARy has been shown to induce STB differentiation 
(119), it is possible that CCNG2 promotes ,the STB differentiation by interacting PPARy. 
I 
Co-immunoprecipitation can be used to de;termine if CCNG2 and PPARy interact. The 
effect of CCNG2 on STB differentiation cc¢ be tested in the presence of PP ARy agonists 
and antagonists. 
In summary, this study demon~trates that miR-378a-5p inhibits trophoblast. 
differentiation into the STB pathway and suggests that these actions may be partially due to 
its inhibition of CCNG2 expression. These findings, together with the planned future 
studies, will provide novel insights into how miRNAs and their regulatory networks control 
trophoblast differentiation and placental development. 
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